Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
Okusaka T, Furuse J, Funakoshi A, Ioka T, Yamao K, Ohkawa S, Boku N, Komatsu Y, Nakamori S, Iguchi H, Ito T, Nakagawa K, Nakachi K.
Okusaka T, et al. Among authors: komatsu y.
Cancer Sci. 2011 Feb;102(2):425-31. doi: 10.1111/j.1349-7006.2010.01810.x. Epub 2010 Dec 22.
Cancer Sci. 2011.
PMID: 21175992
Free article.
Clinical Trial.